Loading
A phase 3 trial testing JNJ-90301900 in head and neck squamous cell carcinoma, now recruiting.
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC is a phase 3 interventional study registered as NCT04892173, led by Johnson & Johnson Enterprise Innovation, and recruiting on the registry. Official title: A Phase 3 Study of NBTXR3 Activated by Investigator's Choice of Radiotherapy Alone or Radiotherapy in Combination With Cetuximab for Platinum-based Chemotherapy-Ineligible Elderly Patients With Locally Advanced Head & Neck Squamous Cell Carcinoma. Planned enrolment is 500 participants (estimated). The study started in 2021-12-10 and primary completion is expected in 2028-06-30. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares JNJ-90301900, Johnson & Johnson.
Shares Johnson & Johnson, Head and neck squamous cell carcinoma.
Shares Johnson & Johnson, Head and neck squamous cell carcinoma.
Shares Johnson & Johnson, Head and neck squamous cell carcinoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/